Comparative Pharmacology
Head-to-head clinical analysis: ALINIA versus EGATEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALINIA versus EGATEN.
ALINIA vs EGATEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitazoxanide is a thiazolide antiparasitic agent that inhibits the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, which is essential for anaerobic energy metabolism in parasites.
Triclabendazole inhibits tubulin polymerization by binding to the colchicine binding site on beta-tubulin, leading to disruption of microtubule formation and paralysis/death of susceptible parasites, particularly Fasciola species.
500 mg orally twice daily for 3 days, with food.
10 mg/kg orally as a single dose, with food; for fascioliasis, 10 mg/kg orally three times daily for 3 days.
None Documented
None Documented
Terminal half-life of tizoxanide is approximately 1.5-2 hours in patients with normal renal function; clinical context: short half-life requires twice-daily dosing.
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 8-12 hours in severe hepatic impairment. Clinical context: supports once-daily dosing.
Fecal (75-85% as tizoxanide), renal (5-10% as tizoxanide and conjugates), biliary (minor).
Primarily fecal (90% as metabolites); renal excretion of unchanged drug is negligible (<1%).
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent